Loading clinical trials...
Loading clinical trials...
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Conditions
Interventions
DS-3201b
DS-3201b
Locations
20
United States
City of Hope National Medical center
Duarte, California, United States
Yale University
New Haven, Connecticut, United States
Emory University
Atlanta, Georgia, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Weill Cornell Medicine
New York, New York, United States
Start Date
March 31, 2016
Primary Completion Date
December 31, 2022
Completion Date
December 31, 2026
Last Updated
February 7, 2025
NCT06090539
NCT07523555
NCT06189391
NCT05006716
NCT06026319
NCT05950165
Lead Sponsor
Daiichi Sankyo Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions